术前新辅助化疗治疗晚期卵巢癌的疗效分析

Analysis of Efficacy of Preoperative Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

目的探讨术前新辅助化疗治疗晚期卵巢癌的疗效。方法对采用术前新辅助化疗(观察组,n=61)或行肿瘤细胞减灭术(对照组,n=58)治疗的119例晚期卵巢癌患者的临床资料进行回顾性分析。结果观察组Ⅲ期患者的新辅助化疗疗效显著大于Ⅳ期患者。观察组患者的手术时间、出血量、最佳减灭率和并发症率都显著优于对照组患者,但是2组患者在术后1年及3年生存率方面差异无统计学意义。结论对于晚期卵巢癌患者,术前新辅助化疗虽然不能提高患者的1年及3年生存率,但是对癌细胞杀伤作用确切,能降低手术难度、减少并发症发生,有利于提高患者的生活质量和改善预后。

Objective To analyze efficacy of preoperative neoadjuvant chemotherapy for advanced ovarian cancer .Meth-ods 119 patients with advanced ovarian cancer were given neoadjuvant chemotherapy (observation group,n=60) or cytoreduc-tive surgery (control group,n=60).Clinical data of the 2 groups were retrospectively analyzed .Results The curative effect of neoadjuvant chemotherapy in stage Ⅲpatients was higher than that of the stage Ⅳpatients in the observation group .The operation time,bleeding,best reduce rate,and complication rate in the observation group were significantly better than those of the control group.However,there were no significant differences in 1-and 3-year survival rates between the 2 groups.Conclusion Preopera-tive neoadjuvant chemotherapy can not improve 1-and 3-year survival rates of advanced ovarian cancer patients ,but has exact anti-tumor effect.It can reduce the difficulty of operation and complications ,and it is beneficial to improve the patient's quality of life and prognosis .